title: Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.
abstract: OBJECTIVE
  To explore the inhibitory effect of bevacizumab, a vascular endothelial growth factor antibody, on angiogenesis in human osteosarcoma of nude mice.
  
  
  METHODS
  Twenty-one nude mice were inoculated with red fluorescent protein (RFP)-labeled human osteosarcoma cell line 143B-RFP, that is, clones that expressed RFP in the cytoplasm, and randomly assigned to one of three groups: G1 (Control group, injected with saline solution); G2 (intraperitoneal bevacizumab 2 mg/kg twice per week) and G3 (intraperitoneal bevacizumab 5 mg/kg, twice per week). The tumor-bearing mice were examined in a fluorescence light box that was illuminated periodically. The primary tumors were measured by fluorescence imaging weekly and their volumes calculated.
  
  
  RESULTS
  The mean tumor volumes were significantly smaller in the G3 (186.4 ± 100.8 mm(3) ) than the control group (587.0 ± 406.8 mm(3) ) (P < 0.05) on Day 31, and again significantly smaller in the G3 (677.3 ± 461.9 mm(3) ) than the control group (3162.6 ± 1529.2 mm(3) ) on Day 38 (P < 0.01). The average tumor volume in the G2 group was 493.5 ± 425.4 mm(3) on Day 31 and 1870.1 ± 1524.8 mm(3) on Day 38. The effect on tumor volume was greater in the G3 than the G2 group. Three mice in the G2 group, four in the G3 group and four in the control group developed lung metastases that were confirmed by pathological examination; these differences were not statistically significant (P < 0.05).
  
  
  CONCLUSIONS
  Bevacizumab exhibits strong antiangiogenesis activity in experimental osteosarcoma in a nude mouse model but does not influence the incidence of lung metastasis. Our findings may have considerable potential for the treatment of osteosarcoma.
authors.affiliation: Department of Orthopaedics, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.|Department of Orthopaedics, Huaian First People's Hospital, Nanjing Medical University, Huaian, China.
authors.forename: Ze-Xue
authors.initials: ZX
authors.lastname: Zhao
authors.affiliation: Department of Orthopaedics, Huaian First People's Hospital, Nanjing Medical University, Huaian, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Orthopaedics, Huaian First People's Hospital, Nanjing Medical University, Huaian, China.
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Liu
authors.affiliation: Department of Orthopaedics, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
authors.forename: Xiao-Zhou
authors.initials: XZ
authors.lastname: Liu
authors.affiliation: Department of Orthopaedics, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
authors.forename: Su-Jia
authors.initials: SJ
authors.lastname: Wu
authors.affiliation: Department of Orthopaedics, Huaian First People's Hospital, Nanjing Medical University, Huaian, China.
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Hu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000818:Animals; D000068258:Bevacizumab / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D045744:Cell Line, Tumor; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental; D012516:Osteosarcoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Bevacizumab; Green fluorescent protein; Mice; Osteosarcoma model; Tumor cells, cultured